Search

Your search keyword '"Jurczyszyn, Artur"' showing total 845 results
Start Over Author "Jurczyszyn, Artur"
845 results on '"Jurczyszyn, Artur"'

2. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

Author

Macauda, Angelica, Clay-Gilmour, Alyssa, Hielscher, Thomas, Hildebrandt, Michelle, Kruszewski, Marcin, Orlowski, Robert, Kumar, Shaji, Ziv, Elad, Orciuolo, Enrico, Brown, Elizabeth, Försti, Asta, Waller, Rosalie, Machiela, Mitchell, Chanock, Stephen, Camp, Nicola, Rymko, Marcin, Raźny, Małgorzata, Cozen, Wendy, Várkonyi, Judit, Piredda, Chiara, Pelosini, Matteo, Belachew, Alem, Subocz, Edyta, Hemminki, Kari, Rybicka-Ramos, Malwina, Giles, Graham, Milne, Roger, Hofmann, Jonathan, Zaucha, Jan, Vangsted, Annette, Goldschmidt, Hartmut, Rajkumar, S, Tomczak, Waldemar, Sainz, Juan, Butrym, Aleksandra, Watek, Marzena, Iskierka-Jazdzewska, Elżbieta, Buda, Gabriele, Robinson, Dennis, Jurczyszyn, Artur, Dudziński, Marek, Martinez-Lopez, Joaquin, Sinnwell, Jason, Slager, Susan, Jamroziak, Krzysztof, Reis, Rui, Weinhold, Niels, Bhatti, Parveen, Carvajal-Carmona, Luis, Zawirska, Daria, Norman, Aaron, Mazur, Grzegorz, Berndt, Sonja, Campa, Daniele, Vachon, Celine, and Canzian, Federico

Subjects
Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Multiple Myeloma, Polymorphism, Single Nucleotide, Risk Factors
Abstract

BACKGROUND: Genome-wide association studies (GWAS) of multiple myeloma in populations of European ancestry (EA) identified and confirmed 24 susceptibility loci. For other cancers (e.g., colorectum and melanoma), risk loci have also been associated with patient survival. METHODS: We explored the possible association of all the known risk variants and their polygenic risk score (PRS) with multiple myeloma overall survival (OS) in multiple populations of EA [the International Multiple Myeloma rESEarch (IMMEnSE) consortium, the International Lymphoma Epidemiology consortium, CoMMpass, and the German GWAS] for a total of 3,748 multiple myeloma cases. Cox proportional hazards regression was used to assess the association between each risk SNP with OS under the allelic and codominant models of inheritance. All analyses were adjusted for age, sex, country of origin (for IMMEnSE) or principal components (for the others) and disease stage (ISS). SNP associations were meta-analyzed. RESULTS: SNP associations were meta-analyzed. From the meta-analysis, two multiple myeloma risk SNPs were associated with OS (P < 0.05), specifically POT1-AS1-rs2170352 [HR = 1.37; 95% confidence interval (CI) = 1.09-1.73; P = 0.007] and TNFRSF13B-rs4273077 (HR = 1.19; 95% CI = 1.01-1.41; P = 0.04). The association between the combined 24 SNP MM-PRS and OS, however, was not significant. CONCLUSIONS: Overall, our results did not support an association between the majority of multiple myeloma risk SNPs and OS. IMPACT: This is the first study to investigate the association between multiple myeloma PRS and OS in multiple myeloma.

Published
2022

3. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

Author

Macauda, Angelica, Briem, Klara, Clay-Gilmour, Alyssa, Cozen, Wendy, Försti, Asta, Giaccherini, Matteo, Corradi, Chiara, Sainz, Juan, Niazi, Yasmeen, ter Horst, Rob, Li, Yang, Netea, Mihai G., Vogel, Ulla, Hemminki, Kari, Slager, Susan L., Varkonyi, Judit, Andersen, Vibeke, Iskierka-Jazdzewska, Elzbieta, Mártinez-Lopez, Joaquin, Zaucha, Jan, Camp, Nicola J., Rajkumar, S. Vincent, Druzd-Sitek, Agnieszka, Bhatti, Parveen, Chanock, Stephen J., Kumar, Shaji K., Subocz, Edyta, Mazur, Grzegorz, Landi, Stefano, Machiela, Mitchell J., Jerez, Andrés, Norman, Aaron D., Hildebrandt, Michelle A. T., Kadar, Katalin, Berndt, Sonja I., Ziv, Elad, Buda, Gabriele, Nagler, Arnon, Dumontet, Charles, Raźny, Malgorzata, Watek, Marzena, Butrym, Aleksandra, Grzasko, Norbert, Dudzinski, Marek, Rybicka-Ramos, Malwina, Matera, Eva-Laure, García-Sanz, Ramón, Goldschmidt, Hartmut, Jamroziak, Krzysztof, Jurczyszyn, Artur, Clavero, Esther, Giles, Graham G., Pelosini, Matteo, Zawirska, Daria, Kruszewski, Marcin, Marques, Herlander, Haastrup, Eva, Sánchez-Maldonado, José Manuel, Bertsch, Uta, Rymko, Marcin, Raab, Marc-Steffen, Brown, Elizabeth E., Hofmann, Jonathan N., Vachon, Celine, Campa, Daniele, and Canzian, Federico

Published
2023
Full Text
View/download PDF

7. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.

Author

Munshi, Pashna, Vesole, David, Jurczyszyn, Artur, Zaucha, Jan, St Martin, Andrew, Davila, Omar, Agrawal, Vaibhav, Badawy, Sherif, Battiwalla, Minoo, Chhabra, Saurabh, Copelan, Edward, Kharfan-Dabaja, Mohamed, Farhadfar, Nosha, Ganguly, Siddhartha, Hashmi, Shahrukh, Krem, Maxwell, Lazarus, Hillard, Malek, Ehsan, Meehan, Kenneth, Murthy, Hemant, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard, Schriber, Jeffrey, Seo, Sachiko, Shah, Gunjan, Solh, Melhem, Tay, Jason, Kumar, Shaji, Qazilbash, Muzaffar, Shah, Nina, Hari, Parameswaran, and DSouza, Anita

Subjects
age, geriatric oncology, myeloma, transplantation, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Progression-Free Survival, Transplantation, Autologous, Treatment Outcome, United States
Abstract

BACKGROUND: Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. METHODS: The authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value

Published
2020

10. The Positive Effects of Training and Time-Restricted Eating in Gut Microbiota Biodiversity in Patients with Multiple Myeloma.

Author

Czerwińska-Ledwig, Olga, Nowak-Zaleska, Alicja, Żychowska, Małgorzata, Meyza, Katarzyna, Pałka, Tomasz, Dzidek, Adrianna, Szlachetka, Agata, Jurczyszyn, Artur, and Piotrowska, Anna

Abstract

Background: The physical activity of different groups of individuals results in the rearrangement of microbiota composition toward a symbiotic microbiota profile. This applies to both healthy and diseased individuals. Multiple myeloma (MM), one of the more common hematological malignancies, predominantly affects older adults. Identifying an appropriate form of physical activity for this patient group remains a challenge. The aim of this study was to investigate the impact of a 6-week Nordic walking (NW) training program combined with a 10/14 time-restricted eating regimen on the gut microbiota composition of multiple myeloma patients. Methods: This study included healthy individuals as the control group (n = 16; mean age: 62.19 ± 5.4) and patients with multiple myeloma in remission (MM group; n = 16; mean age: 65.00 ± 5.13; mean disease duration: 57 months). The training intervention was applied to the patient group and consisted of three moderate-intensity sessions per week, individually tailored to the estimated physical capacity of each participant. The taxonomic composition was determined via 16S rRNA sequencing (V3–V9 regions). The microbiota composition was compared between the patient group and the control group. Results: The alpha and beta diversity metrics for species and genus levels differed significantly between the control and patient groups before the implementation of the NW program. In contrast, no differences were observed between the control and patient groups after the training cycle, indicating that the patients' microbiota changed toward the pattern of the control group. This is confirmed by the lowest values of average dissimilarity between the MMB groups and the control at all taxonomic levels, as well as the highest one between the control group and the MMA patient group. The gut microbiota of the patients was predominantly represented by the phyla Firmicutes, Actinobacteria, Verrucomicrobia, Proteobacteria, and Bacteroidetes. Conclusions: The training, combined with time-restricted eating, stimulated an increase in the biodiversity and taxonomic rearrangement of the gut microbiota species. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

11. Bridging Chemotherapy: Multiple Myeloma

Author

Manier, Salomon, Jurczyszyn, Artur, Vesole, David H., Kröger, Nicolaus, editor, Gribben, John, editor, Chabannon, Christian, editor, Yakoub-Agha, Ibrahim, editor, and Einsele, Hermann, editor

Published
2022
Full Text
View/download PDF

12. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis

Author

Jurczyszyn, Artur, Castillo, Jorge J., Olszewska-Szopa, Magdalena, Kumar, Lalit, Thibaud, Santiago, Richter, Joshua, Flicker, Kari, Fiala, Mark, Vij, Ravi, Yi, Shuhua, Xu, Fang, Silbermann, Rebecca, Gaisan, Carmen Montes, Ocio, Enrique M., Waszczuk-Gajda, Anna, Crusoe, Edvan De Queiroz, Salomon-Perzyński, Aleksander, Hus, Iwona, Valls, Julio Davila, Gozzetti, Alessandro, Czepiel, Jacek, Krzanowska, Katarzyna, Chappell, Aimee, Chellapuram, S.K, Suska, Anna, and Vesole, David H.

Published
2022
Full Text
View/download PDF

13. A polygenic risk score for multiple myeloma risk prediction

Author

Canzian, Federico, Piredda, Chiara, Macauda, Angelica, Zawirska, Daria, Andersen, Niels Frost, Nagler, Arnon, Zaucha, Jan Maciej, Mazur, Grzegorz, Dumontet, Charles, Wątek, Marzena, Jamroziak, Krzysztof, Sainz, Juan, Várkonyi, Judit, Butrym, Aleksandra, Beider, Katia, Abildgaard, Niels, Lesueur, Fabienne, Dudziński, Marek, Vangsted, Annette Juul, Pelosini, Matteo, Subocz, Edyta, Petrini, Mario, Buda, Gabriele, Raźny, Małgorzata, Gemignani, Federica, Marques, Herlander, Orciuolo, Enrico, Kadar, Katalin, Jurczyszyn, Artur, Druzd-Sitek, Agnieszka, Vogel, Ulla, Andersen, Vibeke, Reis, Rui Manuel, Suska, Anna, Avet-Loiseau, Hervé, Kruszewski, Marcin, Tomczak, Waldemar, Rymko, Marcin, Minvielle, Stephane, and Campa, Daniele

Published
2022
Full Text
View/download PDF

15. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

16. The Influence of Nordic Walking Training on the Serum Levels of Sirtuins, FOXO3a, and Vitamin D Metabolites in Patients with Multiple Myeloma.

Author

Czerwińska-Ledwig, Olga, Żychowska, Małgorzata, Jurczyszyn, Artur, Kryst, Joanna, Dzidek, Adrianna, Zuziak, Roxana, Jurczyszyn, Anna, and Piotrowska, Anna

Subjects
VITAMIN D receptors, VITAMIN D metabolism, BODY composition, PHYSICAL fitness, VITAMIN D
Abstract

Background: Multiple myeloma, a malignancy of plasma cells, often involves the disruption of vitamin D metabolism. Vitamin D, acting through its receptor (VDR), affects transcription factors like FOXO and sirtuins, which regulate cellular processes. The impact of physical activity on these markers in multiple myeloma patients is unclear. Therefore, the objective of this study was to evaluate the effects of a 6-week training program on these parameters. Material and methods: The study was completed by 30 patients, including 16 in the Nordic walking training group (TG) and 14 in the control group (non-exercising, CG). All participants underwent a thorough medical interview before starting the project. Venous blood samples were collected from all participants four times—at baseline, after 3 weeks, after 6 weeks, and after 9 weeks (follow-up). The serum concentrations of sirtuin 1, sirtuin 3, Foxo3a, vitamin D receptor (VDR), 25(OH)D3, and 1,25(OH)2D were determined. Body composition, physical fitness, and physical activity level were assessed at baseline and after 6 weeks. Results: No statistically significant changes were observed in the serum levels of sirtuins, the FOXO3a protein, and 1,25(OH)2D. A statistically significant difference was observed in the levels of VDR for both time and group factors, but this was not confirmed in the post hoc test. Vitamin 25(OH)D3 level increased significantly in the study group with time. Conclusions: The applied 6-week Nordic walking training cycle positively affected the level of vitamin 25(OH)D3 but did not influence the rest of the biochemical parameters studied. The obtained results also indicate that the applied intervention is safe for patients and does not interfere with body composition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group.

Author

Waszczuk-Gajda, Anna, Vesole, David H., Małyszko, Jolanta, Jurczyszyn, Artur, Wróbel, Tomasz, Drozd-Sokołowska, Joanna, Boguradzki, Piotr, Mądry, Krzysztof, Tomaszewska, Agnieszka, Biliński, Jarosław, Król, Maria, Niemczyk, Longin, Olszewska-Szopa, Magdalena, Jedrzejczak, Wieslaw W., and Basak, Grzegorz W.

Subjects
STEM cell transplantation, CHRONIC kidney failure, PROGNOSIS, PATIENT selection, MULTIPLE myeloma
Abstract

Introduction: The prognostic factors in autotransplanted multiple myeloma (MM) patients with concomitant advanced chronic kidney disease (CKD) are poorly understood, limited, and controversial. Material and methods: We retrospectively analysed 44 patients with MM and CKD (eGFR < 40 ml/min), present both at diagnosis and at autologous stem cell transplantation (ASCT), with no improvement of renal function in-between. Results: Patients exhibiting deeper paraprotein responses to pre-transplant treatment predicted better response post ASCT (odds ratio (OR) = 11.6, p = 0.028) and longer progression-free survival (PFS) (hazard ratio (HR) = 0.23, p = 0.017). Higher albumin concentration (per increase of 1 g/dl) (HR = 0.41, p = 0.03) and melphalan 140 mg/m2 versus higher melphalan doses (HR = 0.86, p = 0.008) were associated with longer PFS. Performance status (ECOG 0-1 versus ≥ 2) (HR = 0.28, p = 0.0036), higher albumin concentration (HR = 0.43, p < 0.037), and melphalan 140 mg/m2 versus higher melphalan doses (HR = 0.48, p = 0.081) decreased the risk of death. Three of 32 dialysis-dependent patients became dialysis independent (DID), and 5 of 12 in the DID group had eGFR improvement post ASCT. The median PFS was 2.3 years, which was shorter for DID compared to DD patients (0.7 vs. 3.3 years, respectively). The median overall survival (OS) was 3.6 years, there was no difference in median OS between the groups (4.0 vs. 3.5 years, respectively). Conclusions: Optimal patient selection including good performance status and higher albumin concentration (with every increase of 1 g/dl), chemotherapy-responsive disease pre-ASCT, melphalan dose adjusted to CKD, and intensive post-transplant supportive care are crucial to achieve acceptable results of treatment of MM patients with CKD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma

Author

Knop, Stefan, Szarejko, Monika, Grząśko, Norbert, Bringhen, Sara, Trautmann‐Grill, Karolin, Jurczyszyn, Artur, Vacca, Angelo, Khandanpour, Cyrus, Gamberi, Barbara, Pour, Ludek, Iversen, Katrine F., Stumpp, Michael T., Suter, Cosima, Dawson, Keith M., Zitt, Christof, Legenne, Philippe, Stavropoulou, Vaia, Fey, Martin F., Leupin, Nicolas, and Goldschmidt, Hartmut

Published
2024
Full Text
View/download PDF

19. Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.

Author

Charliński, Grzegorz, Grząśko, Norbert, Bołkun, Łukasz, Sawicki, Waldemar, Paczkowska, Edyta, Druzd-Sitek, Agnieszka, Usnarska-Zubkiewicz, Lidia, Butrym, Aleksandra, Wiater, Elżbieta, Boguradzki, Piotr, Budziszewska, Bożena, Wojciechowska, Małgorzata, Mordak-Domagała, Monika, and Jurczyszyn, Artur

Subjects
THERAPEUTIC use of antineoplastic agents, PATIENT compliance, MULTIPLE myeloma, RISK assessment, CROSS-sectional method, SELF-evaluation, QUESTIONNAIRES, DESCRIPTIVE statistics, SURVEYS, LONGITUDINAL method, DRUGS, PATIENT satisfaction, POLISH people, IMMUNOMODULATORS, PATIENTS' attitudes
Abstract

Introduction: Therapeutic adherence (TA) is one of the most important factors influencing the effectiveness of treatment. Oral anti-cancer drugs are increasingly used to treat malignancy including multiple myeloma (MM). Our study aimed to determine TA of patients with MM treated with IMiDs, to identify TA risk factors, and to determine satisfaction with medical care during the treatment with IMiDs. Methods: A cross-sectional survey-based study involving adult patients with MM treated with IMiDs. Results: Between January 2021 and May 2021, 267 patients with MM were enrolled in the study. The dosing schedule was declared as easy by 71.8% of patients, as standard for 24.0%, and difficult for 4.2% of patients. During MM treatment, 85.0% of patients did not skip any IMiDs dose, and 87.6% did not skip the IMiDs dose in the last cycle of chemotherapy. Identified factors affecting TA included the treatment duration and education level. In addition, depending on the patient's well-being, gender, and household companionship influenced TA. Satisfaction with medical care during the treatment with IMiDs was declared by 95.5% of patients with MM. In our cohort, 95.5% of patients were satisfied with the information they received from the hematologist during treatment with IMiDs. Conclusions: Patients with MM treated with IMiDs are highly adherent to treatment. With time from the beginning of treatment, patients need more attention and motivation to adhere to the therapy rules. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation

Author

Abu-Alfa, Ali K., Amer, Hatem, Beutel, Gernot, Chapman, Jeremy, Chen, Xiaohong, Chudek, Jerzy, Cosmai, Laura, Danesi, Romano, De Stefano, Filippo, Iseki, Kunitoshi, Jaimes, Edgar A., Jhaveri, Kenar D., Jurczyszyn, Artur, Kazancioğlu, Rümeyza, Kitchlu, Abhijat, Kollmannsberger, Christian, Lahoti, Amit, Li, Yang, Macía, Manuel, Matsubara, Takeshi, Mitropoulos, Dionysios, Noiri, Eisei, Perazella, Mark A., Ronco, Pierre, Rosner, Mitchell H., Soler Romeo, Maria Jose, Sprangers, Ben, Stadler, Walter M., Stevens, Paul E., Tesař, Vladimír, Torres da Costa e Silva, Verônica, Vesole, David H., Vijayan, Anitha, Viklický, Ondřej, Workeneh, Biruh T., Yanagita, Motoko, Zakharova, Elena, Małyszko, Jolanta, Bamias, Aristotelis, Danesh, Farhad R., Dębska-Ślizień, Alicja, Gallieni, Maurizio, Gertz, Morie A., Kielstein, Jan T., Tesarova, Petra, Wong, Germaine, Cheung, Michael, Wheeler, David C., Winkelmayer, Wolfgang C., and Porta, Camillo

Published
2020
Full Text
View/download PDF

21. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Author

Grosicki, Sebastian, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kriachok, Iryrna, Gavriatopoulou, Maria, Pylypenko, Halyna, Auner, Holger W, Leleu, Xavier, Doronin, Vadim, Usenko, Ganna, Bahlis, Nizar J, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan K, Sinha, Dinesh K, Venner, Christopher P, Garg, Mamta, Gironella, Mercedes, Jurczyszyn, Artur, Robak, Pawel, Galli, Monica, Wallington-Beddoe, Craig, Radinoff, Atanas, Salogub, Galina, Stevens, Don A, Basu, Supratik, Liberati, Anna M, Quach, Hang, Goranova-Marinova, Vesselina S, Bila, Jelena, Katodritou, Eirini, Oliynyk, Hanna, Korenkova, Sybiryna, Kumar, Jeevan, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, White, Darrell, Gatt, Moshe E, Facon, Thierry, Mateos, Maria V, Cavo, Michele, Reece, Donna, Anderson, Larry D, Jr, Saint-Martin, Jean-Richard, Jeha, Jacqueline, Joshi, Anita A, Chai, Yi, Li, Lingling, Peddagali, Vishnuvardhan, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Dimopoulos, Meletios A, Richardson, Paul G, and Delimpasi, Sosana

Published
2020
Full Text
View/download PDF

22. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer

Author

Abu-Alfa, Ali K., Amer, Hatem, Beutel, Gernot, Chapman, Jeremy, Chen, Xiaohong, Chudek, Jerzy, Cosmai, Laura, Danesi, Romano, De Stefano, Filippo, Iseki, Kunitoshi, Jaimes, Edgar A., Jhaveri, Kenar D., Jurczyszyn, Artur, Kazancioğlu, Rümeyza, Kitchlu, Abhijat, Kollmannsberger, Christian, Lahoti, Amit, Li, Yang, Macía, Manuel, Matsubara, Takeshi, Mitropoulos, Dionysios, Noiri, Eisei, Perazella, Mark A., Ronco, Pierre, Rosner, Mitchell H., Soler Romeo, Maria Jose, Sprangers, Ben, Stadler, Walter M., Stevens, Paul E., ladimír Tesař, Torres da Costa e Silva, Verônica, Vesole, David H., Vijayan, Anitha, Viklický, Ondřej, Workeneh, Biruh T., Yanagita, Motoko, Zakharova, Elena, Porta, Camillo, Bamias, Aristotelis, Danesh, Farhad R., Dębska-Ślizień, Alicja, Gallieni, Maurizio, Gertz, Morie A., Kielstein, Jan T., Tesarova, Petra, Wong, Germaine, Cheung, Michael, Wheeler, David C., Winkelmayer, Wolfgang C., and Małyszko, Jolanta

Published
2020
Full Text
View/download PDF

24. Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant

Author

Waszczuk-Gajda, Anna, Małyszko, Jolanta, Vesole, David H., Feliksbrot-Bratosiewicz, Magdalena, Skwierawska, Kamila, Krzanowska, Katarzyna, Kobylińska, Katarzyna, Biecek, Przemysław, Snarski, Emilian, Rodziewicz-Lurzyńska, Anna, Kozłowski, Paweł, Stefaniak, Agnieszka, Drozd-Sokołowska, Joanna, Ziarkiewicz, Mateusz, Vyas, Pyush, Boguradzki, Piotr, Mądry, Krzysztof, Biliński, Jarosław, Tomaszewska, Agnieszka, Maciejewska, Martyna, Urbanowska, Elżbieta, Blajer, Beata, Król, Małgorzata, Król, Maria, Zborowska, Hanna, Jurczyszyn, Artur, Dwilewicz-Trojaczek, Jadwiga, Jedrzejczak, Wieslaw W., and Basak, Grzegorz W.

Published
2020
Full Text
View/download PDF

25. The Impact of a 6-Week Nordic Walking Training Cycle and a 14-Hour Intermittent Fasting on Disease Activity Markers and Serum Levels of Wnt Pathway-Associated Proteins in Patients with Multiple Myeloma

Author

Czerwińska-Ledwig, Olga, primary, Żychowska, Małgorzata, additional, Jurczyszyn, Artur, additional, Kryst, Joanna, additional, Deląg, Jakub, additional, Borkowska, Andżelika, additional, Reczkowicz, Joanna, additional, Pałka, Tomasz, additional, Bujas, Przemysław, additional, and Piotrowska, Anna, additional

Published
2024
Full Text
View/download PDF

27. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

Author

Dean, Eric, Hu, Donglei, Martino, Alessandro, Serie, Daniel, Curtin, Karen, Campa, Daniele, Aftab, Blake, Bracci, Paige, Buda, Gabriele, Zhao, Yi, Caswell-Jin, Jennifer, Diasio, Robert, Dumontet, Charles, Dudziński, Marek, Greenberg, Alexandra, Huntsman, Scott, Jamroziak, Krzysztof, Jurczyszyn, Artur, Kumar, Shaji, Atanackovic, Djordje, Glenn, Martha, Cannon-Albright, Lisa, Jones, Brandt, Lee, Adam, Marques, Herlander, Martin, Thomas, Martinez-Lopez, Joaquin, Rajkumar, Vincent, Sainz, Juan, Vangsted, Annette, Wątek, Marzena, Wolf, Jeffrey, Slager, Susan, Camp, Nicola, Canzian, Federico, Vachon, Celine, Ziv, Elad, and Fejerman, Laura

Subjects
Chromosomes, Human, Pair 16, Genome-Wide Association Study, Humans, Kaplan-Meier Estimate, Multiple Myeloma, Polymorphism, Single Nucleotide
Abstract

Here we perform the first genome-wide association study (GWAS) of multiple myeloma (MM) survival. In a meta-analysis of 306 MM patients treated at UCSF and 239 patients treated at the Mayo clinic, we find a significant association between SNPs near the gene FOPNL on chromosome 16p13 and survival (rs72773978; P=6 × 10(-10)). Patients with the minor allele are at increased risk for mortality (HR: 2.65; 95% CI: 1.94-3.58) relative to patients homozygous for the major allele. We replicate the association in the IMMEnSE cohort including 772 patients, and a University of Utah cohort including 318 patients (rs72773978 P=0.044). Using publicly available data, we find that the minor allele was associated with increased expression of FOPNL and increased expression of FOPNL was associated with higher expression of centrosomal genes and with shorter survival. Polymorphisms at the FOPNL locus are associated with survival among MM patients.

Published
2015

29. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Author

Attal, Michel, Richardson, Paul G., Rajkumar, Vincent, San-Miguel, Jesus, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H. Miles, Macé, Sandrine, Corzo, Kathryn P., Campana, Frank, Le-Guennec, Solenn, Dubin, Franck, Anderson, Kenneth C., Harrison, Simon, Janowski, Wojt, Kerridge, Ian, Spencer, Andrew, Delforge, Michel, Fostier, Karel, Vlummens, Philip, Wu, Ka Lung, Leblanc, Richard, Pavic, Michel, Sebag, Michael, Hajek, Roman, Maisnar, Vladimir, Pour, Ludek, Gregersen, Henrik, Benbouker, Lotfi, Caillot, Denis, Escoffre-Barbe, Martine, Facon, Thierry, Frenzel, Laurent, Hulin, Cyrille, Karlin, Lionel, Kolb, Brigitte, Pegourie, Brigitte, Perrot, Aurore, Tiab, Mourad, Vincent, Laure, Niederwieser, Dietger, Anagnostopoulos, Achilles, Delimpasi, Sosana, Kyrtsonis, Marie-Christine, Symeonidis, Anargyros, Illes, Arpad, Mikala, Gabor, Nagy, Zsolt, Bringen, Sara, Corradini, Paolo, Fabio, Ciceri, Lemoli, Roberto, Liberati, Anna, Nozzoli, Chiara, Zambello, Renato, Iida, Shinsuke, Ikeda, Takashi, Iyama, Satoshi, Matsumoto, Morio, Shimazaki, Chihiro, Sunami, Kazutaka, Suzuki, Kenshi, Uchiyama, Michihiro, Koh, Youngil, Kim, Kihyun, Lee, Jae Hoon, Min, Chang-Ki, Blacklock, Hillary, Goodman, Hugh, Neylon, Annette, Simpson, David, Grosicki, Sebastian, Jurczyszyn, Artur, Walter-Croneck, Adam, Warzocha, Krzysztof, Araujo, Luis, Moreira, Claudia, Doronin, Vadim, Mendeleeva, Larisa, Vorobyev, Vladimir, Vranovsky, Andrej, Alegre, Adrian, Gironella, Mercedes, Gonzalez Perez, Marta Sonia, Montes, Carmen, Ocio, Enrique, Rodriguez, Paula, Hardling, Mats, Lauri, Birgitta, Wang, Ming-Chung, Yeh, Su-Peng, Arat, Mutlu, Demirkan, Fatih, Gulbas, Zafer, Besisik, Sevgi Kalayoglu, Karadogan, Ihsan, Tuglular, Tulin, Unal, Ali, Vural, Filiz, Sive, Jonathan, Streetly, Matthew, Yong, Kwee, Tache, Jason, Richardson, Paul G, Rajkumar, S Vincent, Dimopoulos, Meletios A, Prince, H Miles, Corzo, Kathryn P, and Anderson, Kenneth C

Published
2019
Full Text
View/download PDF

34. Exceptional 30-year survival of a patient with multiple myeloma -- quality of life and management of disease-related symptoms.

Author

Lebowa, Patrycja, Lebowa, Weronika Marzena, and Jurczyszyn, Artur

Abstract

Multiple myeloma (MM) is a chronic plasma cell malignancy with a median survival of about 8--10 years. Despite the development of many new drugs in recent years, disease recurrence is inevitable. The current critical unmet need is the management of heavily pretreated patients with refractory MM. We present the case of a 65-year-old male patient with an exceptionally long-term 30-year course of MM treated with 13 treatment lines. The patient struggles with many disease-related symptoms and treatment toxicity. The patient is currently treated with a triplet regimen including isatuximab, pomalidomide, and dexamethasone. Overall survival of 30 years, which is 3 times greater than the median survival in MM, is still rare, but achievable. In addition to anticancer treatment, supportive care is very important to alleviate myeloma symptoms and improve quality of life. To our knowledge, this is one of the published clinical cases with the longest survival in MM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

Author

Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles

Published
2019
Full Text
View/download PDF

36. Genetically determined telomere length and multiple myeloma risk and outcome

Author

Giaccherini, Matteo, Macauda, Angelica, Orciuolo, Enrico, Rymko, Marcin, Gruenpeter, Karolina, Dumontet, Charles, Raźny, Malgorzata, Moreno, Victor, Buda, Gabriele, Beider, Katia, Varkonyi, Judit, Avet-Loiseau, Hervé, Martinez-Lopez, Joaquín, Marques, Herlander, Watek, Marzena, Sarasquete, Maria Eugenia, Andersen, Vibeke, Karlin, Lionel, Suska, Anna, Kruszewski, Marcin, Abildgaard, Niels, Dudziński, Marek, Butrym, Aleksandra, Nagler, Arnold, Vangsted, Annette Juul, Kadar, Katalin, Waldemar, Tomczak, Jamroziak, Krzysztof, Jacobsen, Svend Erik Hove, Ebbesen, Lene Hyldahl, Taszner, Michał, Mazur, Grzegorz, Lesueur, Fabienne, Pelosini, Matteo, Garcia-Sanz, Ramon, Jurczyszyn, Artur, Demangel, Delphine, Reis, Rui Manuel, Iskierka-Jażdżewska, Elżbieta, Markiewicz, Miroslaw, Gemignani, Federica, Subocz, Edyta, Zawirska, Daria, Druzd-Sitek, Agnieszka, Stępień, Anna, Alonso, M. Henar, Sainz, Juan, Canzian, Federico, and Campa, Daniele

Published
2021
Full Text
View/download PDF

38. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Author

Sonneveld, Pieter, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Quach, Hang, additional, Ho, P. Joy, additional, Beksac, Meral, additional, Hulin, Cyrille, additional, Antonioli, Elisabetta, additional, Leleu, Xavier, additional, Mangiacavalli, Silvia, additional, Perrot, Aurore, additional, Cavo, Michele, additional, Belotti, Angelo, additional, Broijl, Annemiek, additional, Gay, Francesca, additional, Mina, Roberto, additional, Nijhof, Inger S., additional, van de Donk, Niels W.C.J., additional, Katodritou, Eirini, additional, Schjesvold, Fredrik, additional, Sureda Balari, Anna, additional, Rosiñol, Laura, additional, Delforge, Michel, additional, Roeloffzen, Wilfried, additional, Silzle, Tobias, additional, Vangsted, Annette, additional, Einsele, Hermann, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Jurczyszyn, Artur, additional, Lonergan, Sarah, additional, Ahmadi, Tahamtan, additional, Liu, Yanfang, additional, Wang, Jianping, additional, Vieyra, Diego, additional, van Brummelen, Emilie M.J., additional, Vanquickelberghe, Veronique, additional, Sitthi-Amorn, Anna, additional, de Boer, Carla J., additional, Carson, Robin, additional, Rodriguez-Otero, Paula, additional, Bladé, Joan, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

39. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Author

Sonneveld, Pieter, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Quach, Hang, additional, Ho, P. Joy, additional, Beksac, Meral, additional, Hulin, Cyrille, additional, Antonioli, Elisabetta, additional, Leleu, Xavier, additional, Mangiacavalli, Silvia, additional, Perrot, Aurore, additional, Cavo, Michele, additional, Belotti, Angelo, additional, Broijl, Annemiek, additional, Gay, Francesca, additional, Mina, Roberto, additional, Nijhof, Inger S., additional, van de Donk, Niels W.C.J, additional, Katodritou, Eirini, additional, Schjesvold, Fredrik, additional, Sureda Balari, Anna, additional, Rosiñol, Laura, additional, Delforge, Michel, additional, Roeloffzen, Wilfried, additional, Silzle, Tobias, additional, Vangsted, Annette, additional, Einsele, Hermann, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Jurczyszyn, Artur, additional, Lonergan, Sarah, additional, Ahmadi, Tahamtan, additional, Liu, Yanfang, additional, Wang, Jianping, additional, Vieyra, Diego, additional, van Brummelen, Emilie M.J., additional, Vanquickelberghe, Veronique, additional, Sitthi-Amorn, Anna, additional, de Boer, Carla J., additional, Carson, Robin, additional, Rodríguez Otero, Paula, additional, Bladé, Joan, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

43. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017

Author

Dmoszyńska, Anna, Usnarska-Zubkiewicz, Lidia, Walewski, Jan, Lech-Marańda, Ewa, Walter-Croneck, Adam, Pieńkowska-Grela, Barbara, Charliński, Grzegorz, Jędrzejczak, Wiesław Wiktor, Małkowski, Bogdan, Jamroziak, Krzysztof, Druzd-Sitek, Agnieszka, Dytfeld, Dominik, Komarnicki, Mieczysław, Robak, Tadeusz, Jurczyszyn, Artur, Mańko, Joanna, Skotnicki, Aleksander, Giebel, Sebastian, Wiater, Elżbieta, Czepko, Ryszard, Meder, Janusz, and Giannopoulos, Krzysztof

Published
2017
Full Text
View/download PDF

45. Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment—67 Patients Multicenter Analysis.

Author

Charliński, Grzegorz, Steinhardt, Maximilian, Rasche, Leo, Gonzalez-Calle, Veronica, Peña, Camila, Parmar, Harsh, Wiśniewska-Piąty, Katarzyna, Dávila Valls, Julio, Olszewska-Szopa, Magdalena, Usnarska-Zubkiewicz, Lidia, Gozzetti, Alessandro, Ciofini, Sara, Gentile, Massimo, Zamagni, Elena, Kurlapski, Michał, Legieć, Wojciech, Vesole, David H., and Jurczyszyn, Artur

Subjects
CARDIAC amyloidosis, IMMUNOGLOBULIN light chains, SYMPTOMS, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, RESEARCH, MEDICAL records, ACQUISITION of data, CONFIDENCE intervals, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: Light-chain amyloidosis (AL) is a rare multisystem disorder. One of the most common organs involved in AL is the heart. We conducted a multi-center, retrospective analysis of 67 patients with the European 2012 modification of Mayo 2004 stage III cardiac AL. The prognosis of patients with advanced cardiac amyloidosis is poor. The median OS for the entire group was 35 months (95% CI: 7–67). The most important prognostic factors with the most significant impact on OS improvement in patients with modified Mayo stage III cardiac AL identified by multivariate Cox analysis are ECOG PS ≤ 1, NYHA FC ≤ 2, and achieving hematological response ≥ VGPR and cardiac response ≥ PR after first-line treatment. Light-chain amyloidosis (AL) is a rare multisystem disorder characterized by the deposition of misfolded amyloid fibrils derived from monoclonal immunoglobulin light chains in various organs. One of the most common organs involved in AL is the heart, with 50–70% of patients clinically symptomatic at diagnosis. We conducted a multi-center, retrospective analysis of 67 patients diagnosed between July 2012 and August 2022 with the European 2012 modification of Mayo 2004 stage III cardiac AL. The most important factors identified in the univariate Cox analysis contributing to a longer OS included Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1, New York Heart Association functional classification (NYHA FC) ≤ 2, the use of autologous stem cell transplantation (ASCT) after induction treatment, achieving a hematological response (≥very good partial response) and cardiac (≥partial response) response after first-line treatment. The most important prognostic factors with the most significant impact on OS improvement in patients with modified Mayo stage III cardiac AL identified by multivariate Cox analysis are ECOG PS ≤ 1, NYHA FC ≤ 2, and achieving hematological response ≥ VGPR and cardiac response ≥ PR after first-line treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a “real-world” study: Experiences of the Polish Myeloma Group

Author

Charliński, Grzegorz, primary, Grząśko, Norbert, additional, Bołkun, Łukasz, additional, Sawicki, Waldemar, additional, Paczkowska, Edyta, additional, Druzd-Sitek, Agnieszka, additional, Usnarska-Zubkiewicz, Lidia, additional, Butrym, Aleksandra, additional, Wiater, Elżbieta, additional, Boguradzki, Piotr, additional, Budziszewska, Bożena, additional, Wojciechowska, Małgorzata, additional, Mordak-Domagała, Monika, additional, and Jurczyszyn, Artur, additional

Published
2023
Full Text
View/download PDF

48. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

Author

Avivi, Irit, primary, Vesole, David H., additional, Davila-Valls, Julio, additional, Usnarska-Zubkiewicz, Lidia, additional, Olszewska-Szopa, Magdalena, additional, Milunovic, Vibor, additional, Baumert, Bartłomiej, additional, Osękowska, Bogumiła, additional, Kopińska, Anna, additional, Gentile, Massimo, additional, Puertas-Martinez, Borja, additional, Robak, Paweł, additional, Crusoe, Edvan, additional, Rodriguez-Lobato, Luis Gerardo, additional, Gajewska, Małgorzata, additional, Varga, Gergely, additional, Delforge, Michel, additional, Cohen, Yael, additional, Gozzetti, Alessandro, additional, Pena, Camila, additional, Shustik, Chaim, additional, Mikala, Gabor, additional, Zalac, Klara, additional, Alexander, H. Denis, additional, Barth, Peter, additional, Weisel, Katja, additional, Martínez-López, Joaquín, additional, Waszczuk-Gajda, Anna, additional, Krzystański, Mateusz, additional, and Jurczyszyn, Artur, additional

Published
2023
Full Text
View/download PDF

49. P-296 Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy

Author

Mateos, Maria-Victoria, primary, Szarejko, Monika, additional, Bila, Jelena, additional, Schjesvold, Fredrik, additional, Špička, Ivan, additional, Maisnar, Vladimir, additional, Jurczyszyn, Artur, additional, Grudeva-Popova, Zhanet, additional, Hájek, Roman, additional, Usenko, Hanna, additional, Thuresson, Marcus, additional, Norin, Stefan, additional, Jarefors, Sara, additional, Richardson, Paul, additional, and Pour, Ludek, additional

Published
2023
Full Text
View/download PDF

50. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

Author

Pour, Luděk, primary, Szarejko, Monika, additional, Bila, Jelena, additional, Schjesvold, Fredrik H., additional, Spicka, Ivan, additional, Maisnar, Vladimir, additional, Jurczyszyn, Artur, additional, Grudeva-Popova, Zhanet, additional, Hájek, Roman, additional, Usenko, Ganna, additional, Thuresson, Marcus, additional, Norin, Stefan, additional, Jarefors, Sara, additional, Bakker, Nicolaas A., additional, Richardson, Paul G., additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results